BioNTech (UK) Analysis
| 0A3M Stock | USD 118.55 0.15 0.13% |
BioNTech SE is fairly valued with Real Value of 115.6 and Hype Value of 118.53. The main objective of BioNTech stock analysis is to determine its intrinsic value, which is an estimate of what BioNTech SE is worth, separate from its market price. There are two main types of BioNTech's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect BioNTech's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of BioNTech's stock to identify patterns and trends that may indicate its future price movements.
The BioNTech stock is traded in UK on London IL, with the market opening at 08:00:00 and closing at 16:30:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in UK.
BioNTech |
BioNTech Stock Analysis Notes
About 65.0% of the company shares are owned by insiders or employees . The company has Price-to-Book (P/B) ratio of 1.43. In the past many companies with similar price-to-book ratios have beat the market. BioNTech SE has Price/Earnings To Growth (PEG) ratio of 0.05. The entity recorded earning per share (EPS) of 18.0. The firm last dividend was issued on the 6th of June 2022. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. BIONTECH operates under Biotechnology classification in Japan and is traded on IOB. It employs 2500 people. For more info on BioNTech SE please contact the company at 49 6131 9084 0 or go to https://www.biontech.de.BioNTech Quarterly Total Revenue |
|
BioNTech SE Investment Alerts
| BioNTech SE appears to be risky and price may revert if volatility continues | |
| About 65.0% of the company shares are owned by insiders or employees | |
| Latest headline from news.google.com: BioNTechs SWOT analysis oncology pipeline fuels stocks potential amid market volatility - Investing.com |
BioNTech Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 32.61 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioNTech's market, we take the total number of its shares issued and multiply it by BioNTech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.BioNTech Profitablity
BioNTech's profitability indicators refer to fundamental financial ratios that showcase BioNTech's ability to generate income relative to its revenue or operating costs. If, let's say, BioNTech is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, BioNTech's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of BioNTech's profitability requires more research than a typical breakdown of BioNTech's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.48 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.64 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.64. Management Efficiency
BioNTech SE has return on total asset (ROA) of 0.1692 % which means that it generated a profit of $0.1692 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2382 %, meaning that it generated $0.2382 on every $100 dollars invested by stockholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, BioNTech's Non Currrent Assets Other are quite stable compared to the past year. Intangible Assets is expected to rise to about 844.3 M this year, although the value of Total Assets will most likely fall to about 12.1 B.Leadership effectiveness at BioNTech SE is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Operating Margin 0.6395 | Profit Margin 0.4764 | Beta 0.2411 | Return On Assets 0.1692 | Return On Equity 0.2382 |
Technical Drivers
As of the 3rd of December, BioNTech shows the Mean Deviation of 2.44, risk adjusted performance of 0.1102, and Downside Deviation of 3.09. BioNTech SE technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm BioNTech SE downside deviation, standard deviation, information ratio, as well as the relationship between the coefficient of variation and variance to decide if BioNTech SE is priced correctly, providing market reflects its regular price of 118.55 per share.BioNTech SE Price Movement Analysis
The output start index for this execution was twenty-seven with a total number of output elements of thirty-four. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. BioNTech middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for BioNTech SE. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
BioNTech Predictive Daily Indicators
BioNTech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioNTech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
BioNTech Forecast Models
BioNTech's time-series forecasting models are one of many BioNTech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioNTech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About BioNTech Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how BioNTech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioNTech shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BioNTech. By using and applying BioNTech Stock analysis, traders can create a robust methodology for identifying BioNTech entry and exit points for their positions.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. BIONTECH operates under Biotechnology classification in Japan and is traded on IOB. It employs 2500 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding BioNTech to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Stocks Directory Now
Stocks DirectoryFind actively traded stocks across global markets |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.